BRCA Mutations in Latinas

Breast Neoplasms Clinical Trial

Official title: BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects

Status Completed

Clinical Trial Summary

Background:

• BRCA1 and BRCA2 gene mutations have been linked to a higher risk of developing breast cancer and other cancers, and may be associated with types of breast cancer that are more difficult to treat and more likely to recur. New cancer treatments are being developed specifically to treat individuals who have these gene mutations. However, more information is needed about the prevalence of these mutations in minority populations, including Hispanic/Latino populations. To study these populations, researchers are interested in collecting genetic material (DNA) and medical history information from Hispanic/Latino women who have been diagnosed with breast cancer.

Objectives:

• To collect saliva samples and medical and family history information from Hispanic/Latino women with breast cancer.

Eligibility:

• Hispanic/Latino women at least 18 years of age who have been diagnosed with breast cancer.

Design:

• Participants will complete a questionnaire with information about place of birth, languages spoken by parents and grandparents, and information about their breast cancer diagnosis.

• Participants will provide a saliva sample (2 to 3 tablespoons) for analysis.

• No treatment will be provided as part of this protocol.

Clinical Trial Description

BACKGROUND:

• Mutations in the BRCA1 and BRCA2 genes predispose to breast and ovarian cancer, and are increasingly recognized in prostate and pancreatic cancers.

• Basal/ Triple negative breast cancer is associated with BRCA mutations in some ethnicities.However the link between BRCA gene mutations and Basil/ triple negative disease in Hispanic/ Latino women is not known.

• Common recurrent mutations in BRCA1 and BRCA2 exist in Hispanic/ Latino communities.

• New therapies such as PARP inhibitors may be particularly effective in BRCA mutation carriers.

• Therefore a unique opportunity exists to identify women in this underserved minority that may be eligible for and benefit from new targeted therapies.

OBJECTIVES:

• The primary objective is to collect saliva samples and histology data from up to 2000 Hispanic/ Latino subjects with breast cancer as a source of DNA, and to analyze the BRCA1 and BRCA2 genes..

ELIGIBILITY:

• All Hispanics females, over the age of 18, with breast cancer will be eligible.

DESIGN:

• Natural history study of 2000 Hispanic/Latino women with breast cancer, 1000 with triple

negative disease, 1000 without.

• Obtain clinical pathology reports and relevant history data on all subjects.

• Analyze recurrent BRCA1 and BRCA2 mutations ;

Related Conditions & MeSH terms

• Breast Neoplasms

• NCT number: NCT01251900
• Study type: Observational
• Source: National Institutes of Health Clinical Center (CC)
• Status: Completed
• Start date: July 7, 2011